3556-52-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-nitrobenzamide is used as a key intermediate for the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with improved therapeutic properties and efficacy.
Used in Agrochemical Industry:
3-Fluoro-4-nitrobenzamide is utilized as a building block in the synthesis of agrochemicals, contributing to the development of innovative and effective crop protection products.
Used in Fine Chemicals Production:
3-Fluoro-4-nitrobenzamide serves as an important precursor for the preparation of other substituted benzamides, which are essential in the production of various fine chemicals with diverse applications.

Upstream product

• 157665-51-5 3-fluoro-4-nitrobenzoyl chloride 
• 218632-01-0 3-fluoro-4-nitrobenzonitrile 
• 455-38-9 3-fluorobenzoic acid 
• 1711-07-5 3-fluorobenzoyl chloride 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 455-37-8 3-fluorobenzamide 
• 124-43-6 urea hydrogen peroxide adduct 

Downstream Products

• 63069-50-1 4-cyano-2-fluoroaniline 
• 1190762-18-5 methyl 3-(5-carbamoyl-2-nitrophenylamino)propanoate 
• 1190762-17-4 methyl 3-((5-carbamoyl-2-nitrophenyl)(methyl)amino)propanoate 
• 917909-62-7 3-(5-carbamoyl-2-nitrophenoxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 917909-47-8 3-ethoxy-4-amino-benzamide 
• 917908-06-6 3-ethoxy-4-(5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzamide 
• 1332720-99-6 4-(6-chloro-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-3-ethoxy-benzamide 
• 1332721-00-2 4-(6-bromo-5-methyl-thieno[2,3-d]pyrimidin-4-ylamino)-3-ethoxy-benzamide 
• 1190762-21-0 3-(3-hydrazinyl-3-oxopropylamino)-4-nitrobenzamide 
• 1190762-20-9 3-((3-hydrazinyl-3-oxopropyl)(methyl)amino)-4-nitrobenzamide 
• 917909-63-8 4-nitro-3-(pyrrolidin-3-yloxy)-benzamide hydrochloride 
• 917909-65-0 4-amino-3-(1-methanesulfonyl-pyrrolidin-3-yloxy)-benzamide 
• 917909-64-9 3-(1-methanesulfonyl-pyrrolidin-3-yloxy)-4-nitro-benzamide 
• 917909-55-8 4-amino-3-(pyrrolidin-1-yl)-benzamide 

Relevant academic research and scientific papers

NOVEL AROMATIC COMPOUND AND USE THEREOF

Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.

HALOGEN OR CYANO SUBSTITUTED THIENO [2,3-D]PYRIMIDINES HAVING MNK1/MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel thienopyhmidine compounds of general formula (I), pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhib

THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds according to formula (I). Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of

AMINOALYL-IMIDAZOTETRAZINES FOR TREATMENT OF CANCER

The present invention relates to imidazotetrazines of Formula (I) and their use in the treatment of cancer.

THIENOPYRIMIDINES HAVING MNKL /MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositio

THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

BENZAMIDE DERIVATIVES

A compound represented by formula (1): wherein X is a single bond or a substituted or unsubstituted lower alkylene group; Z is a saturated or unsaturated monocyclic hydrocarbon ring group or the like; and each of R1, R2, R3 and R4, which may be the same or different, is a hydrogen atom, a halogen atom, a nitro group, a cyano group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug has inhibitory effect on Rho kinase and hence is useful for treating diseases which are such that morbidity due to them is expected to be improved by inhibition of Rho kinase and secondary effects such as inhibition of the Na+/H+ exchange transport system caused by the Rho kinase inhibition, for example, hypertension.

Aziridinyldinitrobenzamides: Synthesis and structure-activity relationships for activation by E. coli nitroreductase

The 5-aziridinyl-2,4-dinitrobenzamide CB 1954 is a substrate for the oxygen-insensitive nitroreductase (NTR) from E. coli and is in clinical trial in combination with NTR-armed adenoviral vectors in a GDEPT protocol; CB 1954 is also of interest for selective deletion of NTR-marked cells in normal tissues. Since little further drug development has been carried out around this lead, we report here the synthesis of more soluble variants and regioisomers and structure-activity relationship (SAR) studies. The compounds were primarily prepared from the corresponding chloro(di)nitroacids through amide side chain elaboration and subsequent aziridine formation. One-electron reduction potentials [E(1)], determined by pulse radiolysis, were around -400 mV, varying little for aziridinyldinitrobenzamide regioisoiners. Cytotoxicity in a panel of NTR-transfected cell lines showed that in the CB 1954 series there was considerable tolerance of substituted CONHR side chains. The isomeric 2-aziridinyl-3,5-dinitrobenzamide was also selective toward NTR+ve lines but was approximately 10-fold less potent than CB 1954. Other regioisomers were too insoluble to evaluate. While CB 1954 gave both 2- and 4-hydroxylamine metabolites in NTR+ve cells, related analogues with substituted carboxamides gave only a single hydroxylamine metabolite possibly because the steric bulk in the side chain constrains binding within the active site. CB 1954 is also a substrate for the two-electron reductase DT-diaphorase, but all of the other aziridines (regioisomers and close analogues) were poorer substrates with resulting improved specificity for NTR. Bystander effects were determined in multicellular layer cocultures and showed that the more hydrophilic side chains resulted in a modest reduction in bystander killing efficiency. A limited number of analogues were tested for in vivo activity, using a single ip dose to CD-1 nude mice bearing WiDr-NTRneo tumors. The most active of the CB 1954 analogues was a diol derivative, which showed a substantial median tumor growth delay (59 days compared with >85 days for CB 1954) in WiDr xenografts comprising 50% NTR+ve cells. The diol is much more soluble and can be formulated in saline for administration. The results suggest there may be advantages with carefully selected analogues of CB 1954; the weaker bystander effect of its diol derivative may be an advantage in the selective cell ablation of NTR-tagged cells in normal tissues.

Nitrophenylaziridine compounds and their use as prodrugs

A range of aziridin-1-yl nitrobenzamides are provided for use as prodrugs in conjunction with nitroreductase (NR) enzymes. The amides may have 1 or 2-substituents which may be bulky and polar. For example, 5-(aziridin-1-yl)-N-[2-(4-morpholino)ethyl]-2,4-d

INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP

The present application describes inhibitors of factor Xa with a neutral P1 specificity group of formula I: STR1 or pharmaceutically acceptable salt forms thereof, wherein R and E may be groups such as methoxy and halo.